ATE120194T1 - Therapeutische nuleoside. - Google Patents

Therapeutische nuleoside.

Info

Publication number
ATE120194T1
ATE120194T1 AT89306467T AT89306467T ATE120194T1 AT E120194 T1 ATE120194 T1 AT E120194T1 AT 89306467 T AT89306467 T AT 89306467T AT 89306467 T AT89306467 T AT 89306467T AT E120194 T1 ATE120194 T1 AT E120194T1
Authority
AT
Austria
Prior art keywords
nuleosides
therapeutic
therapeutic nuleosides
Prior art date
Application number
AT89306467T
Other languages
English (en)
Inventor
Susan Mary Daluge
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE120194T1 publication Critical patent/ATE120194T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT89306467T 1988-06-27 1989-06-26 Therapeutische nuleoside. ATE120194T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888815265A GB8815265D0 (en) 1988-06-27 1988-06-27 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
ATE120194T1 true ATE120194T1 (de) 1995-04-15

Family

ID=10639435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89306467T ATE120194T1 (de) 1988-06-27 1989-06-26 Therapeutische nuleoside.

Country Status (26)

Country Link
US (5) US5034394A (de)
EP (1) EP0349242B1 (de)
JP (3) JP2875814B2 (de)
KR (1) KR0140532B1 (de)
AP (1) AP101A (de)
AT (1) ATE120194T1 (de)
AU (1) AU636108B2 (de)
CA (1) CA1340589C (de)
CY (1) CY2018A (de)
CZ (1) CZ283786B6 (de)
DE (1) DE68921798T2 (de)
DK (1) DK174668B1 (de)
ES (1) ES2069582T3 (de)
FI (2) FI893113A7 (de)
GB (1) GB8815265D0 (de)
GR (1) GR3015966T3 (de)
HK (1) HK85897A (de)
HU (2) HU206353B (de)
IE (1) IE68038B1 (de)
IL (1) IL90752A (de)
LV (1) LV5781B4 (de)
MY (1) MY104043A (de)
NZ (1) NZ229716A (de)
PT (1) PT90973B (de)
UA (1) UA29382C2 (de)
ZA (1) ZA894837B (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89482B (pt) * 1988-01-20 1994-02-28 Univ Minnesota Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
WO1990006671A2 (en) * 1988-12-12 1990-06-28 Palese Peter M Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
DK0479822T3 (da) * 1989-06-27 2000-03-20 Wellcome Found Terapeutiske nucleosider
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5144034A (en) * 1990-04-06 1992-09-01 Glaxo Inc. Process for the synthesis of cyclopentene derivatives of purines
US5126452A (en) * 1990-04-06 1992-06-30 Glaxo Inc. Synthesis of purine substituted cyclopentene derivatives
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5470857A (en) * 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
US5340816A (en) * 1990-10-18 1994-08-23 E. R. Squibb & Sons, Inc. Hydroxymethyl(methylenecyclopentyl) purines and pyrimidines
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5233041A (en) * 1991-10-07 1993-08-03 Glaxo Group Limited Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinone
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9217823D0 (en) * 1992-08-21 1992-10-07 Glaxo Group Ltd Chemical process
US5329008A (en) * 1993-04-07 1994-07-12 Glaxo Inc. Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CA2164717C (en) * 1993-06-10 2009-10-20 Louis S. Kucera Method of combatting hepatitis b virus infection
DK0705263T3 (da) 1993-06-21 1997-05-05 Merrell Pharma Inc Carbocycliske nukleoside midler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JP4259611B2 (ja) * 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
CA2190202C (en) 1995-11-17 2005-07-26 Nobuya Katagiri Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
CZ298144B6 (cs) 1997-11-27 2007-07-04 Lonza Ag Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
GB9802472D0 (en) 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
US6433170B1 (en) 1998-10-30 2002-08-13 Lonza Group Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
GB9903091D0 (en) * 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
KR20020013937A (ko) 1999-06-28 2002-02-21 다우 케네드 제이. (-)-(1에스,4알) 엔-프로텍티드4-아미노-2-시클로펜텐-1-카르복실레이트 에스테르의제조방법
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CN1486289A (zh) * 2001-05-29 2004-03-31 皇家菲利浦电子有限公司 金属-陶瓷的结合
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
KR100871648B1 (ko) * 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
CA2479037C (en) * 2002-03-15 2010-11-09 Jiri Zemlicka 2-amino-9[(2-hydroxymethyl)cyclopropylidenemethyl]purines as antiviral agents
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
US20050010916A1 (en) * 2003-05-24 2005-01-13 Hagen David A. System for providing software application updates to multiple clients on a network
WO2005026141A2 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Process for preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2160392A2 (de) * 2007-05-03 2010-03-10 Intermune, Inc. Neue makrocyclische inhibitoren der replikation des hepatitis-c-virus
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
EP2116532B1 (de) 2007-06-12 2011-12-07 Concert Pharmaceuticals, Inc. Azapeptid-Derivate als HIV-Protease-Inhibitoren
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
EA201071034A1 (ru) 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2305680A3 (de) * 2009-09-30 2011-05-18 Aurobindo Pharma Limited Neuartige Salze von (1S,4R)-cis-4-[2-amino-6-(cyclopropylamin)-9H-purin-9-yl]-2-cyclopenten-1-methanol
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
AU2012363635B2 (en) 2012-01-03 2015-07-23 Cellceutix Corporation Carbocyclic nucleosides and their pharmaceutical use and compositions
EP2912047B1 (de) 2012-10-29 2016-08-24 Cipla Limited Antivirale phosphonatanaloga und verfahren zur herstellung davon
SG10201704467SA (en) 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
ES2651854T3 (es) 2013-10-03 2018-01-30 Lupin Limited Clorhidrato de abacavir monohidrato cristalino y procedimiento para su preparación
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
KR102252617B1 (ko) * 2014-02-24 2021-05-17 삼성전자 주식회사 데이터 전송 방법 및 이를 구현하는 장치
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
EP3197430A1 (de) 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Langzeitwirkende pharmazeutische zusammensetzungen
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016067182A2 (en) * 2014-10-27 2016-05-06 Granules India Limited Process for the preparation of amino alcohol derivatives or salts thereof
CN104974051A (zh) * 2015-06-30 2015-10-14 苏州开元民生科技股份有限公司 (1S,4R)-cis-4-氨基-2-环戊烯-1-甲醇盐酸盐的合成方法
GB201513601D0 (en) * 2015-07-31 2015-09-16 Univ Liverpool Antiviral compounds
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
WO2017141104A2 (en) * 2016-02-18 2017-08-24 Immune Therapeutics, Inc. Method for inducing a sustained immune response
US20170334913A1 (en) * 2016-05-18 2017-11-23 Cellceutix Corporation Methods Of Preparing Carbocyclic Nucleosides
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2020022486A1 (ja) * 2018-07-27 2020-01-30 富士フイルム株式会社 シクロペンテニルプリン誘導体またはその塩
TW202019941A (zh) 2018-07-27 2020-06-01 日商富士軟片股份有限公司 環丁基嘌呤衍生物或其鹽
CN111393444B (zh) * 2019-01-02 2022-10-28 上海迪赛诺化学制药有限公司 一种阿巴卡韦羟基醋酸酯的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3148363A1 (de) * 1980-12-12 1982-09-16 Toyo Jozo K.K., Shizuoka Neplanocin a-derivate
US4543255A (en) * 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4605659A (en) * 1985-04-30 1986-08-12 Syntex (U.S.A.) Inc. Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals
GR862141B (en) * 1985-08-16 1986-12-23 Glaxo Group Ltd Guanine derivatives
JPS62177234A (ja) * 1986-01-30 1987-08-04 Mitsubishi Heavy Ind Ltd 遠心紡糸によるカ−ボン繊維の製造装置
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US4859677A (en) * 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
JPS6422853A (en) * 1987-07-17 1989-01-25 Asahi Glass Co Ltd Nucleoside analog
US4931559A (en) * 1988-01-20 1990-06-05 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
PT89482B (pt) * 1988-01-20 1994-02-28 Univ Minnesota Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
US4950758A (en) * 1988-01-20 1990-08-21 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4787554A (en) * 1988-02-01 1988-11-29 Honeywell Inc. Firing rate control system for a fuel burner
GB8808458D0 (en) * 1988-04-11 1988-05-11 Metal Box Plc Food containers
US5015739A (en) * 1988-04-22 1991-05-14 Schering Corporation Processes for preparation of cyclopentyl purine derivatives
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
ZA894534B (en) * 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US4939252A (en) * 1989-04-20 1990-07-03 Hoffmann-La Roche Inc. Novel intermediates for the preparation of Carbovir
ES2067693T3 (es) * 1989-10-16 1995-04-01 Chiroscience Ltd Azabicicloheptanona quiral y un procedimiento para su preparacion.
US5126452A (en) * 1990-04-06 1992-06-30 Glaxo Inc. Synthesis of purine substituted cyclopentene derivatives

Also Published As

Publication number Publication date
HU206353B (en) 1992-10-28
FI102680B1 (fi) 1999-01-29
US5087697A (en) 1992-02-11
CA1340589C (en) 1999-06-08
AP8900129A0 (en) 1989-07-31
CZ247092A3 (cs) 1998-04-15
US5089500A (en) 1992-02-18
DK315689A (da) 1989-12-28
JPH0245486A (ja) 1990-02-15
DK174668B1 (da) 2003-08-18
KR910002326A (ko) 1991-01-31
IL90752A (en) 1995-03-15
EP0349242B1 (de) 1995-03-22
DE68921798D1 (de) 1995-04-27
DK315689D0 (da) 1989-06-26
CZ283786B6 (cs) 1998-06-17
FI893113A0 (fi) 1989-06-26
KR0140532B1 (ko) 1998-06-01
US5034394A (en) 1991-07-23
JP2963775B2 (ja) 1999-10-18
LV5781B4 (lv) 1997-04-20
FI893113A7 (fi) 1989-12-28
AP101A (en) 1990-10-23
JP2875814B2 (ja) 1999-03-31
FI102680B (fi) 1999-01-29
PT90973A (pt) 1989-12-29
LV5781A4 (lv) 1996-12-20
IE68038B1 (en) 1996-05-15
JPH0892252A (ja) 1996-04-09
FI894545L (fi) 1989-12-28
MY104043A (en) 1993-10-30
ZA894837B (en) 1991-03-27
HU211537A9 (en) 1995-12-28
HK85897A (en) 1997-06-27
EP0349242A3 (de) 1991-05-29
IE892061L (en) 1989-12-27
GR3015966T3 (en) 1995-07-31
JPH11139976A (ja) 1999-05-25
FI894545A0 (fi) 1989-09-26
GB8815265D0 (en) 1988-08-03
PT90973B (pt) 1994-11-30
EP0349242A2 (de) 1990-01-03
US5206435A (en) 1993-04-27
DE68921798T2 (de) 1995-07-13
US5049671A (en) 1991-09-17
IL90752A0 (en) 1990-01-18
CY2018A (en) 1998-02-20
AU3702589A (en) 1990-01-04
HUT53644A (en) 1990-11-28
ES2069582T3 (es) 1995-05-16
NZ229716A (en) 1992-11-25
AU636108B2 (en) 1993-04-22
UA29382C2 (uk) 2000-11-15

Similar Documents

Publication Publication Date Title
DE68921798D1 (de) Therapeutische Nuleoside.
FI903656A0 (fi) Terapeutiska kinuklidinfoereningar.
FI906367A0 (fi) Terapeutiska nukleosider.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
FI883757A0 (fi) Terapeutiska nukleosider.
FI895509A0 (fi) Terapeutiskt redskap.
FI891327A0 (fi) Roerformig protes.
FI894688A0 (fi) Flytande oralt tagbart terapeutiskt system.
FI890176A0 (fi) Preventivmedel:mikrokondom.
FI881651A0 (fi) Terapeutiska nukleosider.
FI893835L (fi) Laekemedel.
FI904854A0 (fi) Terapeutiska nukleosider.
FI902973A0 (fi) Magnetfaeltsgenerator foer terapeutiska aendamaol.
FI875039A0 (fi) Terapeutiska sammansaettningar foer veterinaermedicinsk anvaendning.
FI893897A0 (fi) Terapeutiska nukleosider.
DE68913289D1 (de) Entseuchungsverfahren.
FI881216A0 (fi) Terapeutiska nukleosider.
DE68912402D1 (de) Massage-Einheit.
FI894321A0 (fi) Terapeutiska aemnen.
DE58900554D1 (de) Aminoguanidinoazine.
DE68910004D1 (de) Therapeutisches Instrument.
FI890316A0 (fi) Foerpackningsfilm.
ATE86241T1 (de) Indanderivate.
NO901574L (no) Terapeutiske midler.
NO901573D0 (no) Terapeutiske midler.

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time